Effect of large doses of methylprednisolone on supratentorial intracranial tumors. A clinical and CAT scan evaluation.
We studied the action of high doses (500 mg/daily for 7 days) of methylprednisolone sodium succinate in 12 patients with supratentorial intracranial tumors. 10 tumors were malignant (5 gliomas and 5 metastases), and 2 benign (meningiomas). Clinical improvement ranged from moderate to marked after 24-48 h of therapy. In the 5 metastases, mean reduction of peritumoral edema was 27%, and in apparent tumor volume was 18%; in the gliomas, corresponding reductions were 31 and 15%. 1 of the meningioma cases showed a decrease in edema volume of 21%. These results indicate that methylprednisolone, at least for a short period of time, produces a definite decrease in apparent tumor size, in addition to the reduction of peritumoral edema.
D000368:Aged; D001254:Astrocytoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology / Q000556:secondary; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008579:Meningioma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D008775:Methylprednisolone / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D011446:Prospective Studies; D014057:Tomography, X-Ray Computed
D008775:Methylprednisolone